×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: melanoma | drug | advanced | Cotellic | inoperable | spread

Advanced Melanoma Drug

Wednesday, 11 November 2015 08:42 AM


The U.S. Food and Drug Administration on Tuesday approved Swiss drugmaker Roche's Cotellic to be used in combination with the company's Zelboraf drug to treat BRAF V600 mutation-positive advanced melanoma.

Roche is counting on the addition of Cotellic to help it revive flagging sales of five-year-old Zelboraf, which dropped 25 percent during the first nine months of 2015 and has been under intense pressure from rivals' drugs as the standard of care moves to combination therapy.

The FDA decision, which had been expected this month, applies to advanced melanoma that spreads to other parts of the body or that cannot be removed by surgery, the U.S. regulatory agency said in a statement.

It follows approval in August of the combination of Cotellic and Zelboraf in treating advanced melanoma in Switzerland. Roche is the world's biggest maker of cancer drugs.

An EU advisory panel has also recommended Cotellic in combination with Zelboraf. A decision by the European Commission is expected by the end of the year.

Last month, Basel-based Roche said final survival data from a Phase III clinical trial showed Cotellic and Zelboraf helped people with previously untreated BRAF V600 mutation-positive advanced melanoma live significantly longer than Zelboraf alone.

Cotellic was discovered by Exelixis Inc and is being developed by Roche and Exelixis.



© 2022 NewsmaxHealth. All rights reserved.


FDA-Approved-Drugs
The U.S. Food and Drug Administration on Tuesday approved Swiss drugmaker Roche's Cotellic to be used in combination with the company's Zelboraf drug to treat BRAF V600 mutation-positive advanced melanoma. Roche is counting on the addition of Cotellic to help it revive...
melanoma, drug, advanced, Cotellic, inoperable, spread
213
2015-42-11
Wednesday, 11 November 2015 08:42 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved